Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease

The current study evaluated amyloid-β oligomers (Aβo) in cerebrospinal fluid as a clinical biomarker for Alzheimer’s disease (AD). We developed a highly sensitive Aβo ELISA using the same N-terminal monoclonal antibody (82E1) for capture and detection. CSF samples from patients with AD, mild cogniti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hölttä, Mikko, Hansson, Oskar, Andreasson, Ulf, Hertze, Joakim, Minthon, Lennart, Nägga, Katarina, Andreasen, Niels, Zetterberg, Henrik, Blennow, Kaj
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2013
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3682966/
https://ncbi.nlm.nih.gov/pubmed/23799095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0066381
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak